Drug intelligence / Profile preview

BCL-5

Development stage: Preclinical
Lead developer: 博仲盛景医药

Overview

BCL-5 is a botanical drug candidate being developed by Botanic Century (博仲盛景医药) for the treatment of Type 2 diabetes. It is a plant-derived extract that functions as a glycosidase inhibitor. By inhibiting glycosidase enzymes in the digestive tract, BCL-5 aims to slow the digestion of complex carbohydrates and the subsequent absorption of glucose in the small intestine, thereby reducing postprandial blood glucose levels. As of the latest reports, the drug is in the preclinical stage of development.

Targets

GH (Growth hormone)

Beyond the preview

Go deeper on BCL-5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCL-5.

Explore the full profile